Douglas Tsao

HC Wainwright & Co. | Healthcare

Douglas Tsao is an analyst from HC Wainwright & Co. specializing in the Healthcare sector. Ranked #437 out of 4496 analysts, they have issued 93 stock ratings with a success rate of 92.02% and an average return of 42.53%.

Douglas Tsao has a well-established track record, with 93 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 92.02% and an average return of 42.53%, underscoring their expertise and ability to identify winning opportunities for investors.

#437

Out of 4496

93

Total Ratings

+92.02%

Success Rate

+42.53%

Average Return

Recent Ratings Analysis

BHVN

Dec 26, 2025

Target

$11.00

Current

$11.15

Performance

0.00%

Douglas Tsao rated BHVN as Neutral on Dec 26, 2025, setting a price target of 11. The Hold stance appears justified, as shares hovered around 11.15 with a 0.00% move.

ROIV

Dec 12, 2025

Target

$26.00

Current

$22.23

Performance

0.59%

On Dec 12, 2025, ROIV was given a Buy rating by Douglas Tsao, with a target price of 26. The stock traded sideways with a 0.59% move, keeping the bullish thesis unresolved.

RZLT

Dec 12, 2025

Target

$14.00

Current

$2.67

Performance

48.33%

RZLT received a Buy rating from Douglas Tsao on Dec 12, 2025, aiming for 14. Momentum has favored the Buy call, with shares climbing from 2.67 to 2.67, rewarding those who trusted the recommendation.

RAPP

Dec 09, 2025

Target

$40.00

Current

$30.20

Performance

5.41%

On Dec 09, 2025, Douglas Tsao published a Buy outlook on RAPP, with a target of 40. Shares gained 5.41%, underscoring the accuracy of the bullish outlook toward 40.

PRAX

Dec 08, 2025

Target

$340.00

Current

$268.95

Performance

-0.75%

Douglas Tsao on Dec 08, 2025 assigned PRAX a Buy rating, with a price target of 340. The recommendation remains pending validation as shares consolidate around 268.95.

DARE

Dec 02, 2025

Target

$12.00

Current

$2.15

Performance

25.00%

On Dec 02, 2025, Douglas Tsao reaffirmed DARE with a Buy rating, targeting 12. The recommendation was supported by strong follow-through as the stock rose from 2.15 to 2.15.

PCRX

Nov 17, 2025

Target

$38.00

Current

$26.51

Performance

11.01%

PCRX was rated Buy by Douglas Tsao on Nov 17, 2025, with a price objective of 38. A bullish response from the market helped close the gap of 11.49 to the target.

TBPH

Nov 11, 2025

Target

$20.00

Current

$18.84

Performance

1.84%

On Nov 11, 2025, Douglas Tsao initiated coverage on TBPH with a Buy rating and target of 20. Neutral price movement of 1.84% leaves room for interpretation.

NERV

Nov 06, 2025

Target

$4.00

Current

$4.19

Performance

15.11%

Douglas Tsao issued a Neutral recommendation for NERV on Nov 06, 2025, price target set at 4. A neutral call gave way to stronger-than-expected performance, closing in on 4.

APLS

Oct 31, 2025

Target

$45.00

Current

$24.97

Performance

16.30%

On Oct 31, 2025, APLS was evaluated by Douglas Tsao, who gave a Buy rating and target of 45. This case illustrates how a timely bullish rating can translate into tangible gains of 16.30%.

ARGX

Oct 31, 2025

Target

$915.00

Current

$844.92

Performance

3.23%

Douglas Tsao rated ARGX as Buy on Oct 31, 2025, setting a price target of 915. Shares have remained stable near 844.92, leaving the 915 target still in play.

CABA

Oct 10, 2025

Target

$16.00

Current

$2.19

Performance

-5.60%

On Oct 10, 2025, CABA was given a Buy rating by Douglas Tsao, with a target price of 16. Despite the Buy call, shares fell from 2.19 to 2.19, challenging the optimistic stance.

PTGX

Oct 08, 2025

Target

$80.00

Current

$88.78

Performance

35.96%

PTGX received a Buy rating from Douglas Tsao on Oct 08, 2025, aiming for 80. Momentum has favored the Buy call, with shares climbing from 88.78 to 88.78, rewarding those who trusted the recommendation.

OTLK

Sep 30, 2025

Target

$1.00

Current

$1.82

Performance

71.70%

On Sep 30, 2025, Douglas Tsao published a Neutral outlook on OTLK, with a target of 1. The Hold call missed some of the bullish momentum as shares advanced toward 1.

ALKS

Sep 09, 2025

Target

$46.00

Current

$28.49

Performance

2.30%

Douglas Tsao on Sep 09, 2025 assigned ALKS a Neutral rating, with a price target of 46. The Hold stance reflected consolidation, as shares held near 28.49.

IMVT

Sep 04, 2025

Target

$35.00

Current

$26.16

Performance

62.28%

On Sep 04, 2025, Douglas Tsao reaffirmed IMVT with a Buy rating, targeting 35. The recommendation was supported by strong follow-through as the stock rose from 26.16 to 26.16.

EVO

Aug 14, 2025

Target

$7.00

Current

$3.11

Performance

-18.59%

EVO was rated Buy by Douglas Tsao on Aug 14, 2025, with a price objective of 7. This case shows how bullish projections can fail, with the stock now below 3.11.

EOLS

Aug 06, 2025

Target

$20.00

Current

$6.90

Performance

8.32%

On Aug 06, 2025, Douglas Tsao initiated coverage on EOLS with a Buy rating and target of 20. The stock’s climb of 8.32% since the call highlights the foresight in the rating.

IRON

Jul 03, 2025

Target

$118.00

Current

$80.33

Performance

46.72%

Douglas Tsao issued a Buy recommendation for IRON on Jul 03, 2025, price target set at 118. Investors following the Buy call captured upside momentum, with shares now at 80.33.

CRNX

Jun 27, 2025

Target

$81.00

Current

$47.96

Performance

60.08%

On Jun 27, 2025, CRNX was evaluated by Douglas Tsao, who gave a Buy rating and target of 81. This case illustrates how a timely bullish rating can translate into tangible gains of 60.08%.

SAGE

Jun 17, 2025

Target

$12.00

Current

$8.68

Performance

-4.82%

Douglas Tsao rated SAGE as Neutral on Jun 17, 2025, setting a price target of 12. The Hold stance appears justified, as shares hovered around 8.68 with a -4.82% move.

ARQT

Apr 03, 2025

Target

$19.00

Current

$28.97

Performance

79.27%

On Apr 03, 2025, ARQT was given a Buy rating by Douglas Tsao, with a target price of 19. The stock rallied 79.27% after the rating, narrowing the gap to the target of 19 and validating the bullish stance.

SCPH

Mar 20, 2025

Target

$18.00

Current

$5.67

Performance

88.37%

SCPH received a Buy rating from Douglas Tsao on Mar 20, 2025, aiming for 18. Momentum has favored the Buy call, with shares climbing from 5.67 to 5.67, rewarding those who trusted the recommendation.

CHRS

Mar 11, 2025

Target

$7.00

Current

$1.33

Performance

26.67%

On Mar 11, 2025, Douglas Tsao published a Buy outlook on CHRS, with a target of 7. Shares gained 26.67%, underscoring the accuracy of the bullish outlook toward 7.

NMRA

Mar 07, 2025

Target

$18.00

Current

$1.78

Performance

19.46%

Douglas Tsao on Mar 07, 2025 assigned NMRA a Buy rating, with a price target of 18. The Buy call aligned well with market performance, producing a gain of 19.46%.

XENE

Feb 24, 2025

Target

$53.00

Current

$44.84

Performance

16.86%

On Feb 24, 2025, Douglas Tsao reaffirmed XENE with a Buy rating, targeting 53. The recommendation was supported by strong follow-through as the stock rose from 44.84 to 44.84.

VRDN

Dec 17, 2024

Target

$34.00

Current

$31.88

Performance

53.12%

VRDN was rated Buy by Douglas Tsao on Dec 17, 2024, with a price objective of 34. A bullish response from the market helped close the gap of 2.12 to the target.

TRVN

Nov 14, 2024

Target

$5.00

Current

$0.01

Performance

-99.29%

On Nov 14, 2024, Douglas Tsao initiated coverage on TRVN with a Neutral rating and target of 5. The rating matched the stock’s inability to hold above 0.012.

MRNS

Oct 25, 2024

Target

$0.00

Current

$0.55

Performance

35.77%

Douglas Tsao issued a Neutral recommendation for MRNS on Oct 25, 2024, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

AEON

Oct 01, 2024

Target

$5.00

Current

$1.02

Performance

-98.61%

On Oct 01, 2024, AEON was evaluated by Douglas Tsao, who gave a Buy rating and target of 5. Investors saw limited payoff as shares fell short of the 5 target.

RVNC

May 13, 2024

Target

$11.00

Current

$3.65

Performance

9.94%

Douglas Tsao rated RVNC as Buy on May 13, 2024, setting a price target of 11. The call has proven timely, with shares rising 9.94% toward the price target of 11.

Frequency Asked Questions

Who is Douglas Tsao?

Douglas Tsao is an analyst from HC Wainwright & Co. specializing in the Healthcare sector.

What is Douglas Tsao's success rate?

Douglas Tsao currently has a success rate of +92.02%.

How many ratings has Douglas Tsao issued?

Douglas Tsao has issued 93 stock ratings so far.

What is the average return of Douglas Tsao's calls?

Their stock ratings have generated an average return of +42.53%.

What is Douglas Tsao's ranking?

Douglas Tsao is ranked #437 out of 4496 analysts.

What types of ratings does Douglas Tsao give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Douglas Tsao?

You can follow Douglas Tsao by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Douglas Tsao?

Their latest rating was a Hold on BHVN issued on 2025-12-26.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep